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Elevated blood pressure (BP) is one of the most prevalent 
cardiovascular risk factors1 and strongly associated with the 
occurrence of major cardiovascular events.2–5 In this con-
text, BP-induced myocardial damage is one of the best stud-
ied consequences of elevated BP, and by itself an important 
predictor of cardiovascular outcomes.6,7 The potential value 
of biomarkers to detect BP-induced left ventricular hyper-
trophy has been described previously.8,9
Cardiac troponins (cTn) are released from myocardial 
cells in case of overt myocardial injury and can be easily 
quantified in this context.10 However, current cTn assays 
have a variable sensitivity to detect cTn levels in lower risk 
populations.11 For example, a prior population-based study 
among middle-aged individuals found detectable high-
sensitivity (hs) cTnT levels in only 25% of the population.12 
Despite this limitation, a significant association with left 
ventricular hypertrophy has been observed in this study, 
underscoring the great potential of cTn for this purpose.12 
On the other hand, one study found that 82.6% of men and 
67.0% of women had detectable cTnI levels in a middle-
aged population, providing evidence that quantification of 
cTn levels is feasible in the majority of individuals.13
Although the clinical utility to detect low levels of cTn 
in healthy population samples is currently unknown, hs-
cTn assays may nevertheless be very useful to improve our 
mechanistic understanding of cTn turnover and its associa-
tions with cardiovascular risk factors. In the current study, 
we therefore aimed to elucidate the distribution of cTn lev-
els in a young and healthy population using a state-of-the-
art high-sensitivity cardiac tropononin (hs-cTnI) assay.11 
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BACKGROUND
The aim of this study was to evaluate the relationship of cardiac tro-
ponin (cTn) levels with conventional and ambulatory blood pressure 
(BP) in young and healthy adults.
METHODS
We performed a population based cross-sectional analysis among 
2,072 young and healthy adults aged 25–41 years free of cardiovascular 
disease and diabetes mellitus. cTnI was measured using a highly sensi-
tive (hs) assay. The relationships of high sensitivity cardiac tropononin 
I (hs-cTnI) with office and 24-hour BP were assessed using multivariable 
regression analyses.
RESULTS
Median age was 37  years and 975 (47%) participants were male. 
hs-cTnI levels were detectable in 2,061 (99.5%) individuals. Median 
(interquartile range) hs-cTnI levels were 0.98 (0.71; 1.64) ng/L among 
men and 0.48 (0.33; 0.71) ng/L among women. Systolic BP, but not 
diastolic BP, gradually increased across hs-cTnI quartiles (118, 120, 121, 
and 122  mm  Hg for conventional BP; P  =  0.0002; 122, 123, 124, and 
124 mm Hg for 24-hour BP, P = 0.0001). In multivariable linear regres-
sion analyses, the β estimates for systolic BP per 1-unit increase in log 
transformed hs-cTnI were 2.52 for conventional BP (P = 0.0001); 2.75 for 
24-hour BP (P < 0.0001); 2.71 and 2.41 (P < 0.0001 and P = 0.0002) for 
day and nighttime BP, respectively. There was a significant relationship 
between hs-cTnI and the Sokolow–Lyon Index (odds ratio (95% confi-
dence interval): 2.09 (1.37; 3.18), P < 0.001).
CONCLUSION
Using a hs assay, hs-cTnI was detectable in virtually all participants of a 
young and healthy population. hs-cTnI was independently associated 
with systolic BP and left ventricular hypertrophy.
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We then sought to assess the relationships of hs-cTnI 
with conventional and ambulatory BP in the same sample 
population.
METHODS
Study participants
Starting in 2010, all inhabitants of the Principality of 
Liechtenstein aged 25 to 41  years were invited to partici-
pate in the ongoing genetic and phenotypic determinants 
of BP and other cardiovascular risk factors (GAPP) study. 
Individuals with a body mass index >35 kg/m2, known car-
diovascular disease, known sleep apnea syndrome, renal 
failure, current intake of antidiabetic drugs, or other severe 
illnesses were excluded. The detailed design and methodol-
ogy of the GAPP cohort have been described previously.14 
Of the 2,159 participants with available hs-cTnI measure-
ments, 87 individuals (4.0%) with no or insufficient ambu-
latory BP information as defined below were excluded, such 
that 2,072 participants remained in the current analyses. 
The study protocol was approved by the local ethics com-
mittee, and informed written consent was obtained from 
each participant.
BP assessment
After at least 5 minutes of rest, three conventional BP meas-
urements were obtained using a validated oscillometric device 
(Microlife BP3AG1, Microlife AG, Widnau, Switzerland). For 
this study, conventional BP was defined as the mean of the 
second and third BP measurement. Ambulatory 24-hour 
BP monitoring was performed using a validated automatic 
device (BR-102 plus, Schiller AG, Baar, Switzerland). BP was 
obtained every 15 minutes from 07.30 to 22.30 and every 30 
minutes during nighttime. If participants had less than 80% 
of valid BP measurements, the BP recording was repeated 
whenever possible. Day and nighttime BP were defined 
according to individually completed diaries. Individuals with 
<10 valid daytime or <5 valid nighttime measurements were 
considered to have insufficient ambulatory BP information 
and were excluded from this study.
Assessment of high-sensitivity Troponin I and other 
biomarkers
A fasting venous blood sample was obtained from each 
participant and stored immediately after centrifugation at 
−80 °C. hs-cTnI was assayed from frozen EDTA plasma sam-
ples using a single-molecule counting technology (Erenna 
Immunoassay System, Singulex, Alameda, CA) with a limit 
of detection of 0.04 ng/L,15 and intra-/inter-assay coefficients 
of variation of 6%/6% at a hs-cTnI concentration of 8.3 ng/L, 
and 8%/9% at a hs-cTnI concentration of 79.7 ng/L. Eleven 
individuals with undetectable hs-cTnI levels in our sample 
were assigned a hs-cTnI value of 0.04 ng/L.
The measurement of other biomarkers used in this analy-
sis has been described in detail previously.14 Glomerular fil-
tration rate was estimated using the formula of the chronic 
kidney disease epidemiology collaboration.16
Assessment of left ventricular hypertrophy
A standardized 12-lead resting electrocardiogram 
(ECG) was obtained in every participant using a vali-
dated device (Schiller AG). Sokolow–Lyon Index (SLI) 
was calculated as the sum of the higher S-Wave in lead 
V1 or V2 and the higher R-Wave in lead V5 or V6. 
A  SLI >3.5 mV was defined to indicate left ventricular 
hypertrophy.17
Assessment of other study variables
Information about personal, medical, lifestyle, and nutri-
tional factors were evaluated using standardized question-
naires. Smoking status was self-assessed as current, past, 
or never. Physical activity was evaluated with the validated 
individual physical activity questionnaire.18 Regular physical 
activity was defined as vigorous physical activity >180 min-
utes per week. Weight and height was measured in a standard-
ized manner by trained study nurses. Body mass index was 
calculated as body weight in kilogram divided by height in 
meters squared.
Statistical analysis
Baseline characteristics were stratified by sex-specific 
hs-cTnI quartiles. Distribution patterns for continuous 
variables were checked using skewness, kurtosis, and 
visual inspection of the histograms. Baseline character-
istics of continuous variables were presented as mean 
± SD or median (interquartile range), and compared 
using analysis of variance or Kruskal–Wallis tests, as 
appropriate. Categorical variables were compared using 
chi-square tests.
Multivariable linear regression models were constructed 
to compare the β-coefficients of various systolic and diastolic 
BP indices (conventional BP, 24-h BP, daytime BP, and night-
time BP) across sex-specific quartiles of hs-cTnI. Because 
the observed associations were approximately linear, we per-
formed additional analyses with hs-cTnI as a continuous vari-
able as the predictor of interest. As the distribution of hs-cTnI 
levels was not normal, this variable was log-transformed for 
all continuous analyses. All analyses were adjusted for a pre-
defined set of potential confounders including age, sex, body 
mass index, current smoking, high density lipoprotein cho-
lesterol, low density lipoprotein cholesterol, hemoglobin A1c, 
glomerular filtration rate, antihypertensive treatment, and 
physical activity.
Multivariable logistic regression analyses were performed 
to correlate sex-specific quartiles of hs-cTnI with a positive 
SLI (SLI >3.5 mV) as a marker of left ventricular hyper-
trophy. In addition to adjusting these models for the same 
covariates indicated above, we also included plasma levels 
of N-Terminal B-type natriuretic peptide (NT-pro BNP) in 
these models.
Vigorous physical activity is a known determinant of left 
ventricular mass,19,20 and may therefore modify the relation-
ship between BP and hs-cTnI. We therefore constructed addi-
tional multivariable regression analyses stratified by physical 
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activity. Formal interaction tests between hs-cTnI and physi-
cal activity were performed in the nonstratified models.
Linear trends were calculated across sex-specific quartiles 
of hs-cTnI. Categorical variables were entered in the multi-
variable models using binary indicator variables. All statis-
tical analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC). A P-value of <0.05 was prespecified to 
indicate statistical significance.
RESULTS
Baseline characteristics of the 2,072 participants according 
to sex-specific quartiles of hs-cTnI are presented in Table 1. 
hs-cTnI levels were detectable in 2,061 (99.5%) individuals. 
Median (interquartile range) hs-cTnI levels were 0.98 (0.71; 
1.64) ng/L among men and 0.48 (0.33; 0.71) ng/L among 
women. Quartile-specific medians (interquartile range) 
were 0.56 (0.46; 0.63), 0.85 (0.78; 0.91), 1.25 (1.13; 1.41), and 
2.58 (1.97; 4.28) for men; and 0.24 (0.18; 0.28), 0.40 (0.37; 
0.43), 0.56 (0.51; 0.62), and 1.11 (0.84; 1.86) for women. 
The 99th percentile of hs-cTnI was 15.76 ng/L in men and 
6.06 ng/L in women, respectively. Participants with higher 
hs-cTnI levels were less often current smokers (P < 0.0001) 
and more often physically active (P < 0.0001). High density 
lipoprotein cholesterol levels increased and glomerular fil-
tration rate decreased across quartiles of hs-cTnI (P = 0.002 
and P < 0.0001, respectively). There were nonlinear differ-
ences across hs-cTnI quartiles for age (P = 0.002) and body 
mass index (P < 0.0001), as shown in Table 1.
BP and high-sensitivity cTnI
Systolic and diastolic BP levels across quartiles of hs-
cTnI are shown in Figure  1. We observed a significant 
increase in mean systolic BP for all BP indices, whereas no 
relationship was seen between hs-cTnI and diastolic BP. 
Pearson correlation coefficients between systolic BP and 
log-transformed hs-cTnI were 0.34, 0.34, 0.34, and 0.28 (all 
P < 0.0001) for office, 24-h, daytime, and nighttime systolic 
BP, respectively.
Multivariable linear regression analyses were consistent 
with a linear relationship between all systolic BP indices and 
hs-cTnI, as shown in Table  2. Compared to individuals in 
the lowest hs-cTnI quartile, those in the highest quartile had 
an increase in systolic BP of approximately 2 mm Hg after 
adjustment for other covariates. On a continuous scale, the 
β-regression coefficients (95% confidence intervals) for log-
transformed hs-cTnI levels and systolic office, 24-h, day and 
nighttime BP were 2.52 (1.24; 3.80), P = 0.0001; 2.75 (1.58; 
3.91), P < 0.0001; 2.71 (1.50; 3.93), P < 0.0001, and 2.41 (1.16; 
3.65), P = 0.0002, respectively. Diastolic BP indices were not 
associated with hs-cTnI in any of these multivariable analy-
ses (Table 2).
Analyses stratified by physical activity are shown in 
Table  3. These analyses consistently showed on average 
stronger associations for the relationship between BP 
and hs-cTnI among physically less active participants, 
although the interaction P values were not statistically 
significant.
Table 1. Baseline characteristics according to sex-specific quartiles of high-sensitivity cardiac troponin I
Quartile 1 (n = 517) Quartile 2 (n = 518) Quartile 3 (n = 519) Quartile 4 (n = 518)
hs-cTnI range, men ≤0.71 ng/l 0.71–0.98, ng/l 0.98–1.63, ng/l >1.63, ng/l
P-value*hs-cTnI range, women ≤0.33, ng/l 0.33–0.47, ng/l 0.47–0.71, ng/l >0.71, ng/l
Age, years 35 (30;40) 37 (31;40) 37 (32;41) 38 (32;41) 0.002
Sex male (%) 243 (47.0) 244 (47.1) 244 (47.0) 244 (47.1) —
BMI, kg/m2 23.4 (21.2; 26.5) 24.5 (22.2; 27.0) 24.6 (22.1; 27.5) 23.9 (22.0; 26.5) <0.0001
Smoking (%) 0.001
 Never 255 (49.3) 277 (53.5) 283 (54.5) 308 (59.5)
 Current 140 (27.1) 124 (23.9) 112 (21.6) 81 (15.6)
 Past 120 (23.2) 116 (22.4) 124 (23.9) 129 (24.9)
Physical activity (%) 212 (41.0) 252 (48.7) 268 (51.6) 295 (57.0) <0.0001
Alcohol consumption, g/d 0.64 (0.00; 1.80) 0.00 (0.00; 1.71) 0.64 (0.00; 1.71) 0.64 (0.00; 2.01) 0.25
Antihypertensive TRT (%) 5 (1.0) 8 (1.6) 9 (1.7) 12 (2.3) 0.40
LDL-C, mmol/l 2.9 (2.3; 3.5) 2.9 (2.4; 3.5) 3.0 (2.4; 3.6) 2.8 (2.4; 3.4) 0.08
HDL-C, mmol/l 1.5 (1.2; 1.8) 1.5 (1.2; 1.8) 1.5 (1.2; 1.8) 1.6 (1.3; 1.9) 0.002
Hemoglobin A1c (%) 5.4 (5.2; 5.6) 5.4 (5.2; 5.7) 5.4 (5.2; 5.6) 5.4 (5.2; 5.6) 0.99
eGFR (ml/min/1.73m2) 112.6 (105.3; 119.6) 112.8 (106.4; 118.5) 111.7 (102.6; 117.7) 110.3 (99.3; 116.6) <0.0001
Creatinine µmol/l 66.3 (56.6; 76.0) 66.3 (58.3; 76.0) 68.0 (58.3; 76.9) 69.0 (58.3; 78.7) 0.01
Data are median (interquartile range) or number (percentage).
Abbreviations: BMI, body mass index; HDL-C, high density lipoprotein cholesterol; hs-cTnI, high sensitivity cardiac Troponin I; LDL-C, low 
density lipoprotein cholesterol; GFR, glomerular filtration rate; TRT, treatment.
*P-values were based on Kruskal–Wallis or chi square tests, as appropriate.
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Left ventricular hypertrophy and high-sensitivity cTnI
Left ventricular hypertrophy according to the SLI criteria 
was present among 267 (13.0 %) individuals. The prevalence 
of left ventricular hypertrophy across quartiles of hs-cTnI was 
11.1, 11.1, 13.4, and 16.3% (P for trend = 0.04). Multivariable 
adjusted odds ratios (95% confidence intervals) across hs-
cTnI quartiles were 1.00 (reference), 1.06 (0.69; 1.63), 1.57 
(1.03; 2.39), and 1.83 (1.20; 2.77) (P for trend  =  0.02), as 
shown in Table 4. Consistent results were observed in analy-
ses stratified by physical activity. Accordingly, none of the P 
values for interaction were statistically significant (data not 
shown).
DISCUSSION
In this large population-based study of young and healthy 
adults without prior cardiovascular disease, we observed 
several important and novel findings. First, using a new 
highly sensitive (hs) assay, we were able to detect hs-cTnI 
levels in virtually all participants. Only eleven of 2,072 
(0.5%) individuals had undetectable hs-cTnI levels in our 
sample population. This prevalence of undetectable cTn lev-
els is lower than in most contemporary hs-cTn assays,12–14 
although a previous study has suggested that several other 
hs-cTnI assays probably have a similar detection rate of over 
80%.11 These data indicate that using the appropriate assay, 
cTn can now be used as a truly quantitative, continuous 
parameter even in healthy, low risk populations.
Second, the 99th percentile of hs-cTnI was 15.76 ng/L in 
men and 6.06 ng/L in women, which is similar to another 
study using the same hs-cTnI assay.21 The 99th percen-
tile is an important parameter in the current definition of 
myocardial infarction,22 and the skewed distribution in the 
current study using the most sensitive troponin assay sug-
gests that this parameter will still be useful in the future.23 
Figure 1. Mean (a) systolic and (b) diastolic BP levels by quartiles of high-sensitivity cardiac troponin I. Values represent mean BP values (in mm Hg) 
across sex-specific quartiles of high-sensitivity cardiac troponin I. P values are based on analysis of variance (ANOVA). Abbreviations:  BP, Blood pressure; 
hs-cTnI, high sensitivity cardiac troponin I; Q, Quartile.
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However, further studies are needed to define the ideal cut-
off, given that current hs-cTnI assays are not standardized 
and the characteristics of the populations studied differ.11,23 
For this reason, it should be highlighted that the clinical 
significance of hs-cTnI levels above the 99th percentile of 
this low-risk population is currently unknown. Finally, the 
Table 2. Multivariable linear regression analyses for the relationship between blood pressure and high-sensitivity cardiac troponin I
Continuous (n = 2072)a Quartile 1 (n = 517) Quartile 2 (n = 518) Quartile 3 (n = 519) Quartile 4 (n = 518) P for trendb
Systolic BP
Office BP 2.52 (1.24; 3.80)** Reference 0.21 (−1.00; 1.43) 1.42 (0.20; 2.64) 2.35 (1.11; 3.58) 0.0007
24-hour BP 2.75 (1.58; 3.91)** Reference 0.67 (−0.44; 1.78) 1.88 (0.77; 3.00) 2.47 (1.34; 3.60) 0.002
Daytime BP 2.71 (1.50; 3.93)** Reference 0.74 (−0.42; 1.90) 1.89 (0.73; 3.06) 2.34 (1.16; 3.52) 0.01
Nighttime BP 2.41 (1.16; 3.65)** Reference 0.44 (−0.75; 1.63) 1.53 (0.33; 2.72) 2.29 (1.09; 3.50) 0.002
Diastolic BP
Office BP 0.47 (−0.50; 1.45) Reference −0.35 (−1.28; 0.58) −0.27 (−1.21; 0.66) 0.37 (−0.57; 1.32) 0.10
24-hour BP 0.62 (−0.26; 1.49) Reference 0.13 (−0.70; 0.97) 0.37 (−0.47; 1.21) 0.38 (−0.47; 1.22) 0.41
Daytime BP 0.44 (−0.49; 1.38) Reference 0.21 (−0.68; 1.10) 0.21 (−0.68; 1.11) 0.16 (−0.74; 1.07) 0.91
Nighttime BP 0.95 (0.05; 1.85)* Reference 0.07 (−0.79; 0.93) 0.70 (−0.17; 1.56) 0.70 (−0.18; 1.57) 0.08
Data are β (95% confidence intervals). All coefficients are adjusted for sex, age, body mass index, current smoking, low density lipoprotein 
cholesterol, high density lipoprotein cholesterol, hemoglobin A1c, glomerular filtration rate, antihypertensive treatment, and physical activity.
aLog-transformed variable.
bP for trend across quartiles of high-sensitivity Troponin I.
Abbreviation: BP, blood pressure.
*P < 0.05; **P < 0.01.
Table 3. Multivariable linear regression analyses for the relationship between blood pressure and high-sensitivity cardiac troponin I stratified 
by physical activity
Variable Physical activitya β (95% confidence intervals) P-value P for interaction
Systolic BP
Office BP Vigorous 0.93 (−0.85; 2.70) 0.30 0.07
Usual 4.19 (2.34; 6.04) <0.0001
24-hour BP Vigorous 1.73 (0.12; 3.35) 0.04 0.20
Usual 3.79 (2.09; 5.48) <0.0001
Daytime BP Vigorous 1.64 (−0.04; 3.32) 0.06 0.18
Usual 3.85 (2.07; 5.63) <0.0001
Nighttime BP Vigorous 1.91 (0.17; 3.65) 0.03 0.90
Usual 2.79 (0.99; 4.59) 0.002
Diastolic BP
Office BP Vigorous 0.38 (−1.76; 0.99) 0.58 0.13
Usual 1.39 (0.001; 2.78) 0.05
24-hour BP Vigorous −0.02 (−1.21; 1.17) 0.97 0.08
Usual 1.29 (0.002; 2.57) 0.05
Daytime BP Vigorous 0.21 (−1.48; 1.07) 0.75 0.08
Usual 1.15 (−0.22; 2.53) 0.10
Nighttime BP Vigorous 0.45 (−0.81; 1.71) 0.48 0.55
Usual 1.37 (0.07; 2.67) 0.04
Data are β (95% confidence intervals).
aVigorous physical activity was defined as vigorous activity > 180 minutes per week. All coefficients are adjusted for sex, age, body mass 
index, current smoking, low density lipoprotein cholesterol, high density lipoprotein cholesterol, hemoglobin A1c, glomerular filtration rate, and 
antihypertensive treatment.
Abbreviation: BP, Blood pressure.
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marked differences between men and women are also in-line 
with prior studies and should be taken into account in future 
definitions.11,21,24
Third, using hs-cTnI as a quantitative variable allowed 
us to detect a significant relationship between hs-cTnI and 
systolic BP, independent of whether we used conventional 
or 24-h ambulatory BP indices. The relationship between 
conventional systolic BP and hs-cTnI has previously been 
observed in an older population.25 We are not aware of large 
studies assessing the relationship between cTn and ambula-
tory 24-h BP. It is noteworthy that hs-cTnI was also associ-
ated with nighttime BP, suggesting that hs-cTnI levels reflect 
increased myocardial stress associated with an increased 
overall BP burden. In this context, it is very plausible that hs-
cTnI was associated with systolic but not diastolic BP, given 
that systolic BP is a much more important determinant for 
cardiac afterload than diastolic BP. In addition, a recent study 
has found differential effects of systolic and diastolic BP on 
adverse cardiac outcomes, providing indirect clinical sup-
port for our findings.26 However, it should also be noted that 
the clinical relevance of small absolute differences of hs-cTn 
levels within the normal range is currently unknown. Future 
studies are needed to assess the clinical role of low levels of 
hs-cTn and the usefulness of their changes over time.
Fourth, hs-cTnI levels were not only associated with 
systolic BP levels, but also with ECG-determined left ven-
tricular hypertrophy. Individuals with hs-cTnI levels in 
the highest quartile had an odds ratio for left ventricular 
hypertrophy of 1.83 (95% confidence interval: 1.20, 2.77; 
P  =  0.005) compared to the lowest quartile. This relation-
ship was independent of systolic BP. Our data are in agree-
ment with prior studies,12,27–29 and suggest that hs-cTnI may 
become an important tool to rule out left ventricular hyper-
trophy.30 Future studies using imaging tools are needed to 
confirm this hypothesis. In addition, hs-cTnI quantified by 
the same assay has recently been associated with the occur-
rence of cardiovascular outcomes in prospective studies, 
further underscoring its potential value in improving car-
diovascular risk stratification.31,32
Based on findings of prior studies, we believe that the rela-
tionships of hs-cTnI with systolic BP and left ventricular hyper-
trophy may be explained by the increased amount of cTn in 
hypertrophic myocardial cells.33,34 Elevated hs-cTnI levels may 
also represent subendocardial hypoperfusion or myocardial 
fibrosis, whose development is supported by high mechanical 
load.35,36 This hypothesis is supported by prior studies show-
ing a higher risk of adverse outcomes among individuals with 
left ventricular hypertrophy on magnetic resonance imaging 
who also have elevated levels of cTnT and NT-proBNP.30,37 In 
our study, the relationship between hs-cTnI and BP seemed 
to be stronger among individuals with lower levels of physical 
activity than among those indicating vigorous physical activity, 
although the P value for interaction was not statistically signifi-
cant. Our data therefore support the concept that hs-cTnI lev-
els mainly reflect BP-induced myocardial hypertrophy among 
individuals with low to moderate physical activity, while 
among those with a high level of physical activity, it may be a 
marker of a physiologically induced increase in left ventricular 
mass, but not reflecting BP-induced damage.19,20 An alterna-
tive explanation for the elevated hs-cTnI levels among those 
with vigorous physical activity may be an increased turnover 
and renewal of cardiomyocytes.38 Future studies are needed to 
elucidate in greater detail these relationships.
Strengths and limitations
Major strengths of this study include the population-
based study design with a large number of well-characterized 
young and healthy adults enrolled, and the concomitant 
recording of both office and 24-h ambulatory BP. Moreover, 
cTn was measured with a very sensitive assay providing 
a detection rate of 99.5%. There are some potential limita-
tions that should be taken into account in the interpretation 
of this study. First, we performed a cross-sectional analy-
sis which does not allow any causal inference. Second, the 
great majority of enrolled individuals were white, and the 
generalizability of our results to other population groups is 
uncertain. However, white women had among the lowest cTn 
levels in a prior study,12 suggesting that the assay used should 
provide similar quantitative results in other ethnic groups as 
well. Third, although well-validated and specific, ECG-based 
measures of left ventricular hypertrophy lack sensitivity. We 
therefore expect even stronger associations in studies where 
left ventricular mass is measured by imaging. Fourth, hs-cTnI 
levels may have been influenced by physical activity prior to 
the blood draw. However, all blood samples were taken in the 
Table 4. Multivariable regression analyses for the relationship between the Sokolow–Lyon Index and high-sensitivity cardiac troponin I
Continuous  
(n = 2060)
Quartile 1  
(n = 513)
Quartile 2  
(n = 516)
Quartile 3  
(n = 515)
Quartile 4  
(n = 516) P for trend*
Sokolow-Lyon Index > 3.5 mV (Logistic regression, OR [95% CI])
Age-, sex-adjusted 
model
2.09 (1.40; 3.11)** Reference 1.01 (0.67; 1.54) 1.36 (0.91; 2.04) 1.83 (1.23; 2.71) 0.005
Fully adjusted 
model
2.09 (1.37; 3.18)** Reference 1.06 (0.69; 1.63) 1.57 (1.03; 2.39) 1.83 (1.20; 2.77) 0.02
Fully adjusted model: sex, age, body mass index, current smoking, low density lipoprotein cholesterol, high density lipoprotein cholesterol, 
hemoglobin A1c, glomerular filtration rate, antihypertensive treatment, physical activity, and nt-pro brain natriuretic peptide. n = 12 with missing 
ECG data.
Abbreviations: OR, odds ratio; CI, confidence intervals.
*P for trend across quartiles of high-sensitivity cardiac Troponin I.
**P < 0.001.
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fasting state early in the morning, and study nurses instructed 
participants to avoid intense physical activity the day before 
study inclusion. Therefore, we believe that the influence of 
vigorous physical activity on hs-cTnI levels should be mini-
mal. Fifth, our study does not provide any direct clinical 
implications. However, we believe that our findings improve 
the understanding of the physiological and pathological 
underpinnings of cTn levels, which will help to define the 
clinical role of modern hs-cTnI assays in the future.
CONCLUSION
Using a highly sensitive assay, cTnI levels were detectable 
in virtually all participants of a young and healthy popula-
tion, thereby revealing a strong relationship of hs-cTnI with 
systolic BP. These tests may therefore be useful to directly 
quantify subclinical myocardial damage associated with 
elevated BP. Prospective studies are needed to verify these 
hypotheses.
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